ClearPoint Neuro, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CLPT research report →
Range $18 – $25
Price Chart
About the company
ClearPoint Neuro, Inc. is a medical technology firm primarily operating within the United States. The company specializes in developing and commercializing sophisticated systems that facilitate minimally invasive brain surgeries, guided by real-time magnetic resonance imaging (MRI) during the procedure.
- CEO
- Joseph Michael Burnett
- IPO
- 2012
- Employees
- 172
- HQ
- Solana Beach, CA, US
Get TickerSpark's AI analysis on CLPT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $221.49M
- P/E
- -5.71
- PEG
- 0.17
- P/S
- 4.87
- P/B
- 7.85
- EV/EBITDA
- -9.27
- Div Yield
- 0.00%
- Gross Margin
- 61.39%
- Op Margin
- -70.56%
- Net Margin
- -79.43%
- ROE
- -170.24%
- ROIC
- -31.12%
Latest fiscal year · YoY change
- Revenue
- $36.97M+17.8%
- Gross Profit
- $22.69M+18.7%
- Op Income
- $-24,164,000
- Net Income
- $-25,540,000-35.0%
- EPS
- $-0.90-28.6%
- OCF Growth
- -167.3%
- FCF Growth
- -165.0%
- 52W High
- $19.63
- 52W Low
- $6.85
- 50D MA
- $10.77
- 200D MA
- $12.59
- Beta
- 1.36
- RSI (14)
- 28
- Avg Volume
- 693.08K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
ClearPoint Neuro delivered 36% year-over-year revenue growth in Q3 2026, but also stepped up investment in its drug-delivery ecosystem, CAL expansion, and field team ahead of 2027 catalysts.· October 28, 2026
- Total revenue rose to $12.1 million, up 36% from $8.9 million in Q3 2025.
- Gross margin was 58%, down 5 points year over year, as CAL overhead and amortization from acquired intangibles weighed on results.
- Operating expenses were $13.4 million, with sales and marketing up 44% and R&D up 16% as the company expanded its clinical and commercial footprint.
- Management highlighted record capital sales, continued CAL build-out, and growing partner activity in cell and gene therapy, including uniQure’s AMT-130 BLA.
- The company ended the quarter with $46.2 million in cash after raising $22 million through its ATM for hiring and expansion costs.
Q3 2026 total revenue was $12.1 million, versus $8.9 million in Q3 2025, up 36% year over year. Biologics and drug delivery revenue was $4.9 million, up 11% from $4.4 million; neurosurgery navigation revenue was $5.4 million, up 59% from $3.4 million; and capital equipment and software revenue was $1.7 million, up 68% from $1.0 million. Gross margin was 58%, down from 63% a year ago. R&D expense was $4.0 million, sales and marketing was $5.5 million, and G&A was $3.8 million; total operating expenses were $13.4 million. Cash and cash equivalents were $46.2 million at September 30, 2026, compared with $45.9 million at December 31, 2025, aided by $22 million in net ATM proceeds and partially offset by $20.1 million of operational cash burn through Q3. For Q4, management indicated the company is tracking toward the implied full-year 2026 revenue guide around a $49 million midpoint, and it said it still feels good about mid-teens growth for 2027, though no formal 2027 guidance was given.
Joe Burnett framed the quarter as progress on ClearPoint’s four-pillar strategy: biologics and drug delivery, neurosurgery navigation, laser therapy/access, and intracranial fluid management. He emphasized the uniQure AMT-130 BLA, multiple expected Phase III partner trials, and the company’s intent to be ready for commercialization with a trained clinical field team and expanded CAL capabilities. His tone was constructive and confident, with repeated emphasis that ClearPoint is investing now to preserve its leadership position in neuro drug delivery and related technologies.
Danilo D’Alessandro focused on operating leverage and the mix of investments. He cited the $12.1 million revenue result, 58% gross margin, and $13.4 million in operating expenses, noting that OpEx was meaningfully lower than the prior quarter and that the first half of the year included heavier one-off integration costs from IRRAS. He also pointed to the $46.2 million cash balance and said the company expects some CAL-related capital expenditures over the next 12 months while aiming to gradually reduce burn over the coming 4 to 6 quarters as revenue outpaces OpEx growth.
Analysts pressed management on the timing and ranking of partner catalysts, especially uniQure’s AMT-130 timeline and whether hospitals are beginning to make preemptive investments ahead of future drug launches. Burnett said the FDA could act on the AMT-130 BLA in the next month or so, with a potential approval window in the middle to second half of next year if the process goes well, while also stressing that multiple Phase III programs are expected to launch over the next 12 to 15 months. In a separate discussion, management said the Q4 revenue step-up should be supported by capital equipment, disposable revenue, and CAL services, and Burnett gave an early view that 2027 base business growth still looks like mid-teens, pending more visibility on regulatory and trial milestones.
The company is growing revenue quickly while building multiple future revenue streams at once, including drug delivery, capital equipment, disposables, CAL services, robotics, focused ultrasound, and IRRAflow. Management also sounded more confident about 2027 catalysts, citing a large and growing partner ecosystem, record capital sales, and potential milestones such as AMT-130 and new IRRAflow product launches.
Gross margin compressed by 5 points year over year, and operating expenses remain elevated because of hiring, CAL build-out, and integration work from IRRAS. Management acknowledged that much of the 2027 upside depends on external timing, including FDA actions on AMT-130, partner trial starts, and the pace of regulatory progress on IRRAflow programs, so the company’s outlook still has meaningful execution and timing risk.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 88.7%
- Shares Outstanding
- 32.05M
- Float Shares
- 28.44M
of shares held by institutions
141 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Mak Capital One LLC | 2.38M | ▲ 474.37K |
| Blackrock, Inc. | 2.15M | ▼ 232.97K |
| Vanguard Group Inc | 1.77M | ▲ 269.04K |
| Vanguard Capital Management LLC | 1.23M | ▼ 1.76K |
| State Street Corp | 875.56K | ▲ 59.01K |
| Geode Capital Management, LLC | 741.55K | ▼ 8.38K |
| Ubs Group AG | 541.60K | ▲ 112.97K |
| Marshall Wace, Llp | 532.93K | ▲ 532.93K |
| Lane Generational LLC | 442.75K | ▼ 2.08K |
| Millennium Management LLC | 357.68K | ▲ 125.70K |
| Brown Advisory Inc | 325.91K | 0 |
| Pekin Hardy Strauss, Inc. | 277.92K | ▲ 134.54K |
Held by 120 ETFs
Biggest fund positions in CLPT by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 1, 26 | Richards Timothy T. | other | 319 |
| Oct 1, 26 | FLETCHER R JOHN | other | 993 |
| Sep 2, 26 | BURNETT JOSEPH | other | 12,517 |
| Sep 2, 26 | BURNETT JOSEPH | other | 12,517 |
| Jul 1, 26 | FLETCHER R JOHN | other | 662 |
| Jul 1, 26 | Richards Timothy T. | other | 222 |
| Jun 30, 26 | STIGALL L. JEREMY | other | 1,781 |
| Jun 30, 26 | D'Alessandro Danilo | other | 1,085 |
| Jun 30, 26 | BURNETT JOSEPH | other | 1,361 |
| Jun 29, 26 | BURNETT JOSEPH | other | 20,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CLPT coverage
Recent articles, reports, and earnings notes.
No research on CLPT yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CLPT report →INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ClearPoint Neuro, Inc. - CLPT
prnewswire.com · Nov 12
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ClearPoint Neuro, Inc. - CLPT
globenewswire.com · Nov 10
ClearPoint Neuro: Momentum Building Across The Business
seekingalpha.com · Nov 9
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ClearPoint Neuro, Inc. - CLPT
prnewswire.com · Nov 5
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ClearPoint Neuro, Inc. - CLPT
globenewswire.com · Nov 3
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ClearPoint Neuro, Inc. - CLPT
prnewswire.com · Oct 29
What ClearPoint Neuro (CLPT) Said on Its Q3 Earnings Call
marketbeat.com · Oct 28
ClearPoint Neuro, Inc. (CLPT) Reports Q3 Loss, Misses Revenue Estimates
zacks.com · Oct 28
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.